

## ASX Announcement

### Regeneus and Cryosite partner for the development and manufacture of human stem cell products

Sydney, Australia – 21 August 2014

Regeneus (ASX: RGS) and Cryosite (ASX: CTE) announced today that they have signed an agreement to collaborate on the development and manufacture of new stem cell products for human applications.

Key elements of the agreement include:

- Regeneus will provide technology, know-how and research facilities to assist Cryosite with the development of methods for the expansion of cord tissue-derived mesenchymal stem cells (MSCs);
- Cryosite will provide production facilities for Regeneus' off-the-shelf allogeneic stem cell product for human osteoarthritis (Progenza). The product, to be used for clinical trial purposes, will be manufactured within Cryosite's good manufacturing practice (GMP) clean room facilities by Regeneus staff; and
- The companies will jointly explore new product development and manufacturing opportunities.

Cryosite's Acting CEO, Graeme Moore, said: "There are a number of synergies between our two companies that we are focused on bringing to commercial fruition. The agreement has a direct and immediate effect on increasing Cryosite's revenues and will enable the further development of a new cord tissue derived stem cell product that will complement our established cord blood stem cell banking service. Cord tissue contains MSCs that are not generally found in cord blood".

Professor Graham Vesey, Regeneus CEO, stated that: "This agreement allows Regeneus to cost effectively fast-track the production of Regeneus' off-the shelf Progenza product for preclinical and clinical trials for market entry into Japan".

Progenza is Regeneus' off-the-shelf stem cell product for human OA that is manufactured by collecting a small amount of fat from a human donor. The stem cells from the fat are expanded by tissue culture, dispensed into vials and frozen. Several hundred thousand doses of the product can be produced from fat from one donor thus allowing a true pharmaceutical industry style stem cell product.

Professor Vesey also stated: "Our relationship with Cryosite is developing into a strong partnership and we anticipate that it will continue to grow over time. Cryosite currently provides stem cell handling and storage services for Regeneus' personalised stem cell therapy for human OA, HiQCell. Cryosite's capabilities in the manufacturing and storage of GMP cell-based products in a TGA licensed facility complements Regeneus' product development and early stage commercialisation capabilities. We foresee a future where our two companies use these capabilities together to develop and supply a range of regenerative medicine products".

ENDS

**To subscribe to Regeneus news feeds please refer to the link below:**

**<http://regeneus.com.au/investor-centre/subscribe>**

**Contacts and further information:****Investors:**

Sandra McIntosh  
Company Secretary  
Regeneus Ltd  
T: +61 2 9499 8010  
E: [investors@regeneus.com.au](mailto:investors@regeneus.com.au) or go to [www.regeneus.com.au](http://www.regeneus.com.au)

**Media:**

Clare Serafini  
Communications Manager, Regeneus Ltd  
T: +61 2 9499 8010  
Mobile: 0417 299 081  
E: [clare.serafini@regeneus.com.au](mailto:clare.serafini@regeneus.com.au) or go to [www.regeneus.com.au](http://www.regeneus.com.au)

**Cryosite**

Graeme Moore  
Acting CEO  
Cryosite Ltd  
T: +61 2 8865 2000  
Mobile: +61 409 109 089  
E: [graeme.moore@cryosite.com](mailto:graeme.moore@cryosite.com) or go to [www.cryosite.com](http://www.cryosite.com)

**About Regeneus:**

Regeneus Ltd (ASX: RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.

Regeneus' lead product for the veterinary health market is CryoShot, a clinical stage allogeneic adipose stem cell product for the treatment of canine and equine OA. CryoShot canine is scheduled for a US registration trial in Q4 2015. Regeneus has a clinical stage autologous therapeutic cancer vaccine, Kvax, which will commence marketing trials in the US and Australia in Q4 2014. The company has also acquired in July 2014 the exclusive rights to commercialise the vaccine technology for human applications and plans to commence a first-in-man study in Q1 2015.

**About Cryosite:**

Cryosite (ASX: CTE) is a unique Australian biotech company that pioneered private autologous Cord Blood Banking in 2002, directed allogeneic Family Banking in 2011, and in 2014 has developed and commercialised methods for the cryopreservation and expansion of MCS's from umbilical cord tissue.

Cryosite also provides specialised Bio-repository, Clinical Trials Logistics, Commercial Drug Distribution, contract Cellular Therapies manufacturing and associated consultancy services to commercial clients both within Australia and internationally. Cryosite's facilities are NATA accredited (ISO15189, ISO17025) and its Cord Blood Stem Cell cryopreservation and storage laboratories are fully licensed by the TGA.